EVALUATEMEDTECH WORLD PREVIEW 2018, OUTLOOK TO 2024 The new edition of the EvaluateMedTech World Preview is now available. The report shows that the medical device and diagnostics industry will reach $595 billion in sales by 2024 (CAGR of 5.6%). Medtronic is forecast to continue to be the leading medtech company in 2024 with sales of $39 billion. The EvaluateMedTech World Preview 2018

highlights

WORLD PREVIEW 2018, OUTLOOK TO 2024 Foreword 4 In the 2018 edition of the EvaluateMedTech® World Preview we can reveal that the global medtech industry is expected to grow at 5.6% per year (CAGR) ORPHAN DRUG REPORT 2018 Worldwide orphan drug sales are forecasted to grow at a CAGR of 11% from 2018-2024. Our 2018 Orphan Drug Report shows continuing unmet medical need is set to fuel the growth of the worldwide orphan drug market with sales predicted to grow at over 11% a year to $262bn by 2024. By 2024, orphan drugs will represent over a fifth of the

worldwide

EUROPEAN PHARMA MARKET OUTLOOK TO 2022 European Pharma Market Outlook to 2022 Top selling marketed products in 2022 Size of the market in EU-5 set to grow by 25% between 2017-2022 with a CAGR of SHIFTING CAR-TS INTO A HIGHER GEAR Shifting CAR-Ts Into a Higher Gear Jacob Plieth & Edwin Elmhirst –

June 2016

EVALUATEMEDTECH WORLD PREVIEW 2017, OUTLOOK TO 2022 Worldwide Medtech Sales Forecast to Reach $522 Billion by 2022 with a CAGR of 5.1% between 2016 and 2022. The new edition of EvaluateMedTech World Preview 2017, Outlook to 2022 shows Medtronic was the leading medtech company in 2016 with sales of almost $30bn. They will retain the crown in 2022 with sales forecast to reach $37.7bn. EVALUATEPHARMA WORLD PREVIEW 2017, OUTLOOK TO 2022 Pricing pressure causes worldwide drug sales forecasts to fall for first time in 10 years. The new edition of our annual report, EvaluatePharma World Preview 2017, Outlook to 2022 discusses the impact that i ncreased scrutiny around the pricing of medicines is starting to have on drug sales growth. Despite consensus forecasts for worldwide drug sales hitting $1.06trn in 2022, this is down from EVALUATEMEDTECH WORLD PREVIEW 2016, OUTLOOK TO 2022 EvaluateMedTech ® World Preview 2016, Outlook to 2022 5th Edition –

October 2016

EVALUATEPHARMA WORLD PREVIEW 2017, OUTLOOK TO 2022 EvaluatePharma ® World Preview 2017, Outlook to 2022 10th Edition –

June 2017

BUDGET-BUSTERS: THE SHIFT TO HIGH-PRICED INNOVATOR DRUGS EvaluatePharma® Foreword: Move to Higher Priced Drugs Within the Top 100 Selling Drugs in the USA Over the last five years a fundamental shift in spending trends towards high-priced medicines, EVALUATEMEDTECH WORLD PREVIEW 2018, OUTLOOK TO 2024 The new edition of the EvaluateMedTech World Preview is now available. The report shows that the medical device and diagnostics industry will reach $595 billion in sales by 2024 (CAGR of 5.6%). Medtronic is forecast to continue to be the leading medtech company in 2024 with sales of $39 billion. The EvaluateMedTech World Preview 2018

highlights

WORLD PREVIEW 2018, OUTLOOK TO 2024 Foreword 4 In the 2018 edition of the EvaluateMedTech® World Preview we can reveal that the global medtech industry is expected to grow at 5.6% per year (CAGR) ORPHAN DRUG REPORT 2018 Worldwide orphan drug sales are forecasted to grow at a CAGR of 11% from 2018-2024. Our 2018 Orphan Drug Report shows continuing unmet medical need is set to fuel the growth of the worldwide orphan drug market with sales predicted to grow at over 11% a year to $262bn by 2024. By 2024, orphan drugs will represent over a fifth of the

worldwide

EUROPEAN PHARMA MARKET OUTLOOK TO 2022 European Pharma Market Outlook to 2022 Top selling marketed products in 2022 Size of the market in EU-5 set to grow by 25% between 2017-2022 with a CAGR of SHIFTING CAR-TS INTO A HIGHER GEAR Shifting CAR-Ts Into a Higher Gear Jacob Plieth & Edwin Elmhirst –

June 2016

EVALUATEMEDTECH WORLD PREVIEW 2017, OUTLOOK TO 2022 Worldwide Medtech Sales Forecast to Reach $522 Billion by 2022 with a CAGR of 5.1% between 2016 and 2022. The new edition of EvaluateMedTech World Preview 2017, Outlook to 2022 shows Medtronic was the leading medtech company in 2016 with sales of almost $30bn. They will retain the crown in 2022 with sales forecast to reach $37.7bn. EVALUATEPHARMA WORLD PREVIEW 2017, OUTLOOK TO 2022 Pricing pressure causes worldwide drug sales forecasts to fall for first time in 10 years. The new edition of our annual report, EvaluatePharma World Preview 2017, Outlook to 2022 discusses the impact that i ncreased scrutiny around the pricing of medicines is starting to have on drug sales growth. Despite consensus forecasts for worldwide drug sales hitting $1.06trn in 2022, this is down from EVALUATEMEDTECH WORLD PREVIEW 2016, OUTLOOK TO 2022 EvaluateMedTech ® World Preview 2016, Outlook to 2022 5th Edition –

October 2016

EVALUATEPHARMA WORLD PREVIEW 2017, OUTLOOK TO 2022 EvaluatePharma ® World Preview 2017, Outlook to 2022 10th Edition –

June 2017

BUDGET-BUSTERS: THE SHIFT TO HIGH-PRICED INNOVATOR DRUGS EvaluatePharma® Foreword: Move to Higher Priced Drugs Within the Top 100 Selling Drugs in the USA Over the last five years a fundamental shift in spending trends towards high-priced medicines,

EVALUATE

Key Highlights: There are now 268 combination trials involving Keytruda and 242 with Opdivo, of which 86 combine Opdivo with Yervoy. Keytruda’s dominance comes as the drug continues to impress in clinical trials. The number of studies combining anti-PD-1/PD-L1s with chemotherapy have surged, potentially spurred by Roche’s efforts

with

EVALUATEPHARMA WORLD PREVIEW 2018, OUTLOOK TO 2024 Key Highlights. Prescription drug sales expected to reach $1.2trn in 2024 (+6.4% CAGR 2018-2024) Oncology continues to be a key industry driver, with a forecasted CAGR of 12% from 2017 to 2024. Novartis will be the leading prescription drug company in 2024 with sales of $53.2bn. Humira remains the top selling drug in 2024, despite a CAGR

of -3%

EVALUATEMEDTECH WORLD PREVIEW 2017, OUTLOOK TO 2022 Worldwide Medtech Sales Forecast to Reach $522 Billion by 2022 with a CAGR of 5.1% between 2016 and 2022. The new edition of EvaluateMedTech World Preview 2017, Outlook to 2022 shows Medtronic was the leading medtech company in 2016 with sales of almost $30bn. They will retain the crown in 2022 with sales forecast to reach $37.7bn. YOUR COMMERCIAL LENS ON THE PHARMACEUTICAL INDUSTRY EvaluatePharma gives you the time and confidence to turn knowledge into insight, and insight into action Comprehensive commercial data EvaluatePharma is your most comprehensive source of commercial information on the past, present and EVALUATEMEDTECH WORLD PREVIEW 2015, OUTLOOK TO 2020 EvaluateMedTech ® World Preview 2015, Outlook to 2020 4th Edition –

October 2015

PHARMACEUTICAL INNOVATION IN EUROPE Two factors are at play behind the projected impact of new therapies: 1. A new stream of potential medical breakthroughs which are likely to transform many therapy areas. Oncology – driven by the uptake of PD-1/PD-L1 inhibitors (e.g. Opdivo, Keytruda) – is going through a medical revolution that is likely to re-shape the current clinical

guidelines.

EP VANTAGE 2018 PREVIEW EP Vantage 2018 Preview Amy Brown, Edwin Elmhirst and Jon Gardner –

December 2017

WORLD PREVIEW 2014, OUTLOOK TO 2020 F or the first time in the pharmaceutical industry’s history, the consensus forecast of worldwide prescription drug sales is set to exceed one trillion dollars, reaching $1,017bn by 2020, equating to an WORLD PREVIEW 2014, OUTLOOK TO 2020 The third edition of the EvaluateMedTech® World Preview reveals that the medtech market is expected to grow at 5% per year (CAGR) between 2013 and 2020, achieving global sales of $514bn in 2020 (page 6). The analysis is based on in-depth forecast models for the ORPHAN DRUG REPORT 2014 Welcome to the EvaluatePharma® Orphan Drug Report 2014 The second edition of EvaluatePharma’s Orphan Drug Report brings together many of our analyses to provide top-level insight, from the world’s financial markets, into the expected EVALUATEMEDTECH WORLD PREVIEW 2018, OUTLOOK TO 2024 The new edition of the EvaluateMedTech World Preview is now available. The report shows that the medical device and diagnostics industry will reach $595 billion in sales by 2024 (CAGR of 5.6%). Medtronic is forecast to continue to be the leading medtech company in 2024 with sales of $39 billion. The EvaluateMedTech World Preview 2018

highlights

WORLD PREVIEW 2018, OUTLOOK TO 2024 Foreword 4 In the 2018 edition of the EvaluateMedTech® World Preview we can reveal that the global medtech industry is expected to grow at 5.6% per year (CAGR) ORPHAN DRUG REPORT 2018 Worldwide orphan drug sales are forecasted to grow at a CAGR of 11% from 2018-2024. Our 2018 Orphan Drug Report shows continuing unmet medical need is set to fuel the growth of the worldwide orphan drug market with sales predicted to grow at over 11% a year to $262bn by 2024. By 2024, orphan drugs will represent over a fifth of the

worldwide

EUROPEAN PHARMA MARKET OUTLOOK TO 2022 European Pharma Market Outlook to 2022 Top selling marketed products in 2022 Size of the market in EU-5 set to grow by 25% between 2017-2022 with a CAGR of SHIFTING CAR-TS INTO A HIGHER GEAR Shifting CAR-Ts Into a Higher Gear Jacob Plieth & Edwin Elmhirst –

June 2016

EVALUATEMEDTECH WORLD PREVIEW 2017, OUTLOOK TO 2022 Worldwide Medtech Sales Forecast to Reach $522 Billion by 2022 with a CAGR of 5.1% between 2016 and 2022. The new edition of EvaluateMedTech World Preview 2017, Outlook to 2022 shows Medtronic was the leading medtech company in 2016 with sales of almost $30bn. They will retain the crown in 2022 with sales forecast to reach $37.7bn. EVALUATEPHARMA WORLD PREVIEW 2017, OUTLOOK TO 2022 Pricing pressure causes worldwide drug sales forecasts to fall for first time in 10 years. The new edition of our annual report, EvaluatePharma World Preview 2017, Outlook to 2022 discusses the impact that i ncreased scrutiny around the pricing of medicines is starting to have on drug sales growth. Despite consensus forecasts for worldwide drug sales hitting $1.06trn in 2022, this is down from EVALUATEMEDTECH WORLD PREVIEW 2016, OUTLOOK TO 2022 EvaluateMedTech ® World Preview 2016, Outlook to 2022 5th Edition –

October 2016

EVALUATEPHARMA WORLD PREVIEW 2017, OUTLOOK TO 2022 EvaluatePharma ® World Preview 2017, Outlook to 2022 10th Edition –

June 2017

BUDGET-BUSTERS: THE SHIFT TO HIGH-PRICED INNOVATOR DRUGS EvaluatePharma® Foreword: Move to Higher Priced Drugs Within the Top 100 Selling Drugs in the USA Over the last five years a fundamental shift in spending trends towards high-priced medicines, EVALUATEMEDTECH WORLD PREVIEW 2018, OUTLOOK TO 2024 The new edition of the EvaluateMedTech World Preview is now available. The report shows that the medical device and diagnostics industry will reach $595 billion in sales by 2024 (CAGR of 5.6%). Medtronic is forecast to continue to be the leading medtech company in 2024 with sales of $39 billion. The EvaluateMedTech World Preview 2018

highlights

WORLD PREVIEW 2018, OUTLOOK TO 2024 Foreword 4 In the 2018 edition of the EvaluateMedTech® World Preview we can reveal that the global medtech industry is expected to grow at 5.6% per year (CAGR) ORPHAN DRUG REPORT 2018 Worldwide orphan drug sales are forecasted to grow at a CAGR of 11% from 2018-2024. Our 2018 Orphan Drug Report shows continuing unmet medical need is set to fuel the growth of the worldwide orphan drug market with sales predicted to grow at over 11% a year to $262bn by 2024. By 2024, orphan drugs will represent over a fifth of the

worldwide

EUROPEAN PHARMA MARKET OUTLOOK TO 2022 European Pharma Market Outlook to 2022 Top selling marketed products in 2022 Size of the market in EU-5 set to grow by 25% between 2017-2022 with a CAGR of SHIFTING CAR-TS INTO A HIGHER GEAR Shifting CAR-Ts Into a Higher Gear Jacob Plieth & Edwin Elmhirst –

June 2016

EVALUATEMEDTECH WORLD PREVIEW 2017, OUTLOOK TO 2022 Worldwide Medtech Sales Forecast to Reach $522 Billion by 2022 with a CAGR of 5.1% between 2016 and 2022. The new edition of EvaluateMedTech World Preview 2017, Outlook to 2022 shows Medtronic was the leading medtech company in 2016 with sales of almost $30bn. They will retain the crown in 2022 with sales forecast to reach $37.7bn. EVALUATEPHARMA WORLD PREVIEW 2017, OUTLOOK TO 2022 Pricing pressure causes worldwide drug sales forecasts to fall for first time in 10 years. The new edition of our annual report, EvaluatePharma World Preview 2017, Outlook to 2022 discusses the impact that i ncreased scrutiny around the pricing of medicines is starting to have on drug sales growth. Despite consensus forecasts for worldwide drug sales hitting $1.06trn in 2022, this is down from EVALUATEMEDTECH WORLD PREVIEW 2016, OUTLOOK TO 2022 EvaluateMedTech ® World Preview 2016, Outlook to 2022 5th Edition –

October 2016

EVALUATEPHARMA WORLD PREVIEW 2017, OUTLOOK TO 2022 EvaluatePharma ® World Preview 2017, Outlook to 2022 10th Edition –

June 2017

BUDGET-BUSTERS: THE SHIFT TO HIGH-PRICED INNOVATOR DRUGS EvaluatePharma® Foreword: Move to Higher Priced Drugs Within the Top 100 Selling Drugs in the USA Over the last five years a fundamental shift in spending trends towards high-priced medicines,

EVALUATE

Key Highlights: There are now 268 combination trials involving Keytruda and 242 with Opdivo, of which 86 combine Opdivo with Yervoy. Keytruda’s dominance comes as the drug continues to impress in clinical trials. The number of studies combining anti-PD-1/PD-L1s with chemotherapy have surged, potentially spurred by Roche’s efforts

with

EVALUATEPHARMA WORLD PREVIEW 2018, OUTLOOK TO 2024 Key Highlights. Prescription drug sales expected to reach $1.2trn in 2024 (+6.4% CAGR 2018-2024) Oncology continues to be a key industry driver, with a forecasted CAGR of 12% from 2017 to 2024. Novartis will be the leading prescription drug company in 2024 with sales of $53.2bn. Humira remains the top selling drug in 2024, despite a CAGR

of -3%

EVALUATEMEDTECH WORLD PREVIEW 2017, OUTLOOK TO 2022 Worldwide Medtech Sales Forecast to Reach $522 Billion by 2022 with a CAGR of 5.1% between 2016 and 2022. The new edition of EvaluateMedTech World Preview 2017, Outlook to 2022 shows Medtronic was the leading medtech company in 2016 with sales of almost $30bn. They will retain the crown in 2022 with sales forecast to reach $37.7bn. YOUR COMMERCIAL LENS ON THE PHARMACEUTICAL INDUSTRY EvaluatePharma gives you the time and confidence to turn knowledge into insight, and insight into action Comprehensive commercial data EvaluatePharma is your most comprehensive source of commercial information on the past, present and EVALUATEMEDTECH WORLD PREVIEW 2015, OUTLOOK TO 2020 EvaluateMedTech ® World Preview 2015, Outlook to 2020 4th Edition –

October 2015

PHARMACEUTICAL INNOVATION IN EUROPE Two factors are at play behind the projected impact of new therapies: 1. A new stream of potential medical breakthroughs which are likely to transform many therapy areas. Oncology – driven by the uptake of PD-1/PD-L1 inhibitors (e.g. Opdivo, Keytruda) – is going through a medical revolution that is likely to re-shape the current clinical

guidelines.

EP VANTAGE 2018 PREVIEW EP Vantage 2018 Preview Amy Brown, Edwin Elmhirst and Jon Gardner –

December 2017

WORLD PREVIEW 2014, OUTLOOK TO 2020 F or the first time in the pharmaceutical industry’s history, the consensus forecast of worldwide prescription drug sales is set to exceed one trillion dollars, reaching $1,017bn by 2020, equating to an WORLD PREVIEW 2014, OUTLOOK TO 2020 The third edition of the EvaluateMedTech® World Preview reveals that the medtech market is expected to grow at 5% per year (CAGR) between 2013 and 2020, achieving global sales of $514bn in 2020 (page 6). The analysis is based on in-depth forecast models for the ORPHAN DRUG REPORT 2014 Welcome to the EvaluatePharma® Orphan Drug Report 2014 The second edition of EvaluatePharma’s Orphan Drug Report brings together many of our analyses to provide top-level insight, from the world’s financial markets, into the expected EVALUATEMEDTECH WORLD PREVIEW 2018, OUTLOOK TO 2024EVALUATEMEDTECH WORLD PREVIEW 2019EVALUATEPHARMA WORLD PREVIEW 2018EVALUATEPHARMA

WORLD PREVIEW 2020

Worldwide medtech sales forecast to reach $595bn by 2024. The new edition of the EvaluateMedTech World Preview is now available. The report shows that the medical device and diagnostics industry will reach $595 billion in sales by 2024 (CAGR of 5.6%). WORLD PREVIEW 2018, OUTLOOK TO 2024 Foreword 4 In the 2018 edition of the EvaluateMedTech® World Preview we can reveal that the global medtech industry is expected to grow at 5.6% per year (CAGR) ORPHAN DRUG REPORT 2018 Worldwide orphan drug sales are forecasted to grow at a CAGR of 11% from 2018-2024. Our 2018 Orphan Drug Report shows continuing unmet medical need is set to fuel the growth of the worldwide orphan drug market with sales predicted to grow at over 11% a year to $262bn by

2024.

SHIFTING CAR-TS INTO A HIGHER GEAR Shifting CAR-Ts Into a Higher Gear Jacob Plieth & Edwin Elmhirst –

June 2016

EUROPEAN PHARMA MARKET OUTLOOK TO 2022 European Pharma Market Outlook to 2022 Top selling marketed products in 2022 Size of the market in EU-5 set to grow by 25% between 2017-2022 with a CAGR of EVALUATEMEDTECH WORLD PREVIEW 2017, OUTLOOK TO 2022 EvaluateMedTech World Preview 2017, Outlook to 2022 Worldwide Medtech Sales Forecast to Reach $522 Billion by 2022 with a CAGR of 5.1% between 2016 and 2022 EVALUATEPHARMA WORLD PREVIEW 2017, OUTLOOK TO 2022 Pricing pressure causes worldwide drug sales forecasts to fall for first time in 10 years. The new edition of our annual report, EvaluatePharma World Preview 2017, Outlook to 2022 discusses the impact that i ncreased scrutiny around the pricing of medicines is starting to have on drug sales growth. Despite consensus forecasts for worldwide drug sales hitting $1.06trn in 2022, this is down from EVALUATEMEDTECH WORLD PREVIEW 2016, OUTLOOK TO 2022EVALUATEMEDTECH WORLD PREVIEWEVALUATEMEDTECH WORLD PREVIEW 2019 EvaluateMedTech ® World Preview 2016, Outlook to 2022 5th Edition –

October 2016

EVALUATEPHARMA WORLD PREVIEW 2017, OUTLOOK TO 2022 EvaluatePharma ® World Preview 2017, Outlook to 2022 10th Edition –

June 2017

BUDGET-BUSTERS: THE SHIFT TO HIGH-PRICED INNOVATOR DRUGS EvaluatePharma® Foreword: Move to Higher Priced Drugs Within the Top 100 Selling Drugs in the USA Over the last five years a fundamental shift in spending trends towards high-priced medicines, EVALUATEMEDTECH WORLD PREVIEW 2018, OUTLOOK TO 2024EVALUATEMEDTECH WORLD PREVIEW 2019EVALUATEPHARMA WORLD PREVIEW 2018EVALUATEPHARMA

WORLD PREVIEW 2020

Worldwide medtech sales forecast to reach $595bn by 2024. The new edition of the EvaluateMedTech World Preview is now available. The report shows that the medical device and diagnostics industry will reach $595 billion in sales by 2024 (CAGR of 5.6%). WORLD PREVIEW 2018, OUTLOOK TO 2024 Foreword 4 In the 2018 edition of the EvaluateMedTech® World Preview we can reveal that the global medtech industry is expected to grow at 5.6% per year (CAGR) ORPHAN DRUG REPORT 2018 Worldwide orphan drug sales are forecasted to grow at a CAGR of 11% from 2018-2024. Our 2018 Orphan Drug Report shows continuing unmet medical need is set to fuel the growth of the worldwide orphan drug market with sales predicted to grow at over 11% a year to $262bn by

2024.

SHIFTING CAR-TS INTO A HIGHER GEAR Shifting CAR-Ts Into a Higher Gear Jacob Plieth & Edwin Elmhirst –

June 2016

EUROPEAN PHARMA MARKET OUTLOOK TO 2022 European Pharma Market Outlook to 2022 Top selling marketed products in 2022 Size of the market in EU-5 set to grow by 25% between 2017-2022 with a CAGR of EVALUATEMEDTECH WORLD PREVIEW 2017, OUTLOOK TO 2022 EvaluateMedTech World Preview 2017, Outlook to 2022 Worldwide Medtech Sales Forecast to Reach $522 Billion by 2022 with a CAGR of 5.1% between 2016 and 2022 EVALUATEPHARMA WORLD PREVIEW 2017, OUTLOOK TO 2022 Pricing pressure causes worldwide drug sales forecasts to fall for first time in 10 years. The new edition of our annual report, EvaluatePharma World Preview 2017, Outlook to 2022 discusses the impact that i ncreased scrutiny around the pricing of medicines is starting to have on drug sales growth. Despite consensus forecasts for worldwide drug sales hitting $1.06trn in 2022, this is down from EVALUATEMEDTECH WORLD PREVIEW 2016, OUTLOOK TO 2022EVALUATEMEDTECH WORLD PREVIEWEVALUATEMEDTECH WORLD PREVIEW 2019 EvaluateMedTech ® World Preview 2016, Outlook to 2022 5th Edition –

October 2016

EVALUATEPHARMA WORLD PREVIEW 2017, OUTLOOK TO 2022 EvaluatePharma ® World Preview 2017, Outlook to 2022 10th Edition –

June 2017

BUDGET-BUSTERS: THE SHIFT TO HIGH-PRICED INNOVATOR DRUGS EvaluatePharma® Foreword: Move to Higher Priced Drugs Within the Top 100 Selling Drugs in the USA Over the last five years a fundamental shift in spending trends towards high-priced medicines,

EVALUATE

Immuno-oncology combination trials triple since 2015 Keytruda now partner of choice. This report examines the explosion in the number of clinical trials using anti-PD-1 and anti-PD-L1 antibodies combined with other therapeutic approaches. EVALUATEPHARMA WORLD PREVIEW 2018, OUTLOOK TO 2024 Key Highlights. Prescription drug sales expected to reach $1.2trn in 2024 (+6.4% CAGR 2018-2024) R&D spend is forecast at 16.9% of prescription sales in 2024 EVALUATEMEDTECH WORLD PREVIEW 2017, OUTLOOK TO 2022 Key Highlights. Total value of medtech M&A deals rises by a massive 178% in H1 2017. In vitro diagnostics is expected to remain the largest medtech segment in 2022 with annual sales of $70bn; Roche remains top player with expected sales of $12.8bn in 2022 YOUR COMMERCIAL LENS ON THE PHARMACEUTICAL INDUSTRY EvaluatePharma gives you the time and confidence to turn knowledge into insight, and insight into action Comprehensive commercial data EvaluatePharma is your most comprehensive source of commercial information on the past, present and EVALUATEMEDTECH WORLD PREVIEW 2015, OUTLOOK TO 2020 EvaluateMedTech ® World Preview 2015, Outlook to 2020 4th Edition –

October 2015

PHARMACEUTICAL INNOVATION IN EUROPE Two factors are at play behind the projected impact of new therapies: 1. A new stream of potential medical breakthroughs which are likely to transform many therapy areas. Oncology – driven by the uptake of PD-1/PD-L1 inhibitors (e.g. Opdivo, Keytruda) – is going through a medical revolution that is likely to re-shape the current clinical

guidelines.

EP VANTAGE 2018 PREVIEW EP Vantage 2018 Preview Amy Brown, Edwin Elmhirst and Jon Gardner –

December 2017

WORLD PREVIEW 2014, OUTLOOK TO 2020 F or the first time in the pharmaceutical industry’s history, the consensus forecast of worldwide prescription drug sales is set to exceed one trillion dollars, reaching $1,017bn by 2020, equating to an WORLD PREVIEW 2014, OUTLOOK TO 2020 The third edition of the EvaluateMedTech® World Preview reveals that the medtech market is expected to grow at 5% per year (CAGR) between 2013 and 2020, achieving global sales of $514bn in 2020 (page 6). The analysis is based on in-depth forecast models for the ORPHAN DRUG REPORT 2014 Welcome to the EvaluatePharma® Orphan Drug Report 2014 The second edition of EvaluatePharma’s Orphan Drug Report brings together many of our analyses to provide top-level insight, from the world’s financial markets, into the expected Skip to main content

* Contact Us __ __

* Sign Up

* Subscriber Sign In __

__ Switch language

* " class="en is-active">">English * " class="ja">">Japanese

NAVIGATION

サイト内検索

__

*

COVID-19

* COVID-19 Update

* Evaluate Vantage COVID-19 Report * COVID-19 Stories from Evaluate Vantage * Evaluate’s Business Continuity Plan

*

What We Do

* Commercial Intelligence

*

Products

* Evaluate Pharma

* Evaluate Omnium

* Evaluate Epi

* Japan Drug Forecasts * Europe Drug Forecasts

*

Evaluate Custom Solutions

*

Evaluate Vantage

* News

* Analysis

* Policy & Pricing

* Data Insights

* Events

* Medtech

* Therapy Areas

* Editorial Team

* About Evaluate Vantage * Evaluate for Biotech

*

How We Can Help You

* Pharma and Biotech

* Medtech

* Financial Services * Management Consultancies

* Service Providers

* Customer Testimonials * Thought Leadership

*

About Us

* Press Releases

* Media Coverage

* Executive Team

* Vision & History

* Contact Us

* Sign Up for Evaluate Vantage

* Talent

* Subscriber Sign In

Search

__

HOW DO YOU ACCURATELY ANALYSE ALL OF THE DRUGS THAT ARE BEING DEVELOPED WHEN IN EVERY 20 ONLY ONE WILL MAKE IT TO THE MARKET PLACE ?

LEARN MORE

EVALUATE RADICALLY TRANSFORMS YOUR CONFIDENCE IN STRATEGIC PORTFOLIO

DECISIONS.

When you partner with Evaluate, our constantly expanding solutions and transparent methodologies and datasets are instantly at your disposal, along with expert, personalised support. Evaluate provides a complete and dynamic valuation of pharma assets, turning understanding into insight, and insight into action.

HOW WE CAN HELP YOU

We use cookies on this website. By using this site, you agree that we may store and access cookies on your device. Find out more.

OK

Market Reports

Thought Leadership

Read our wide range of complimentary market reports covering sector performance and valuation, market trends and global forecasts, including our annual Evaluate Pharma World Preview.

READ OUR REPORTS

OUR PRODUCTS

Evaluate Pharma

Get a global view of the pharmaceutical market’s past, present and future performance with over two decades of commercial data and consensus forecasts to 2026.

FIND OUT MORE

OUR SERVICES

Custom Solutions

Improve your strategic decision-making with customised, data-driven solutions that draw on our collaborative team of industry experts and trusted commercial intelligence.

FIND OUT MORE

Independent, data-driven daily news and analysis on pharma, biotech

and medtech.

June 04, 2021

ASCO 2021 – ALKERMES’S DISAPPOINTMENT HONES MELANOMA NICHE FOCUS Alkermes plays up responses in mucosal melanoma, but those hoping for an IL-2 renaissance might be disappointed.

June 04, 2021

ASCO 2021 – MERUS’S SLIGHT IMPROVEMENT MIGHT NOT WIN OVER

INVESTORS

The group still has its eye on accelerated approval, though genetic testing casts a long shadow.

June 03, 2021

REPLIMUNE HEADS FOR THE LIVER

June 03, 2021

ASCO 2021 JUSTIFIES NOVARTIS’S RADIOLIGAND VISION

June 03, 2021

ASCO 2021 – BRISTOL MAKES MORE PROGRESS IN STOMACH CANCER Independent, data-driven daily news and analysis on pharma, biotech

and medtech.

Sign up

Open modal

Evaluate HQ

44-(0)20-7377-0800

Evaluate Americas

+1-617-573-9450

Evaluate APAC

+81-(0)80-1164-4754

FOOTER MENU

* 規約と条件

* Privacy Policies

* Cookie Policy

* __

* __

* __

� Copyright 2021 Evaluate Ltd.

Tweet

Share

Email

Live Chat is Online

Chatting

0

×

–

undefined

Chat Input Box

Chat

Powered by